Tag Archives: DESTINY-Breast06 trial

Roche Expands FDA Approval of PATHWAY® HER2 Test for HER2-Ultralow Breast Cancer Status

(IN BRIEF) Roche has announced that the FDA has expanded the approval of its PATHWAY® HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify HER2-ultralow status in HR-positive, HER2-negative metastatic breast cancer patients. This new approval offers a potential treatment … Read the full press release